[1]	Siegel RL, Giaquinto AN, Jemal A. Cancer statistics,2024[J]. CA Cancer J Clin, 2024, 74(1):12-49.DOI:10.3322/caac.21820. Cited in this article [1]

[2]	Kim J, Gosnell JE, Roman SA. Geographic influences in the global rise of thyroid cancer[J]. Nat Rev Endocrinol, 2020, 16(1):17-29.DOI:10.1038/s41574-019-0263-x. Cited in this article [1]

[3]	Hundahl SA, Fleming ID, Fremgen AM, et al. A national cancer data base report on 53 856 cases of thyroid carcinoma treated in the U.S.,1985-1995[J]. Cancer, 1998, 83(12):2638-2648.DOI:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1. Cited in this article [1]

[4]	James BC, Aschebrook-Kilfoy B, White MG, et al. Quality of life in thyroid cancer-assessment of physician perceptions[J]. J Surg Res, 2018, 226(6):94-99.DOI:10.1016/j.jss.2017.11.069. Cited in this article [1]

[5]

Quagliariello V, Armenia E, Aurilio C, et al. New treatment of medullary and papillary human thyroid cancer:biological effects of hyaluronic acid hydrogel loaded with quercetin alone or in combination to an inhibitor of aurora kinase[J]. J Cell Physiol, 2016, 231(8):1784-1795.DOI:10.1002/jcp.25283. Cited in this article [1]

[6]	Lin JD, Hsueh C, Chao TC. Long-term follow-up of the therapeutic outcomes for papillary thyroid carcinoma with distant metastasis[J]. Medicine (Baltimore), 2015, 94(26):e1063. DOI:10.1097/md.0000000000001063. Cited in this article [1]

[7]

Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1):1-133.DOI:10.1089/thy.2015.0020. Cited in this article [1]

[8]	张少航, 牛丽娟. 超声引导下穿刺粗针病理学和细胞学及细针细胞学在甲状腺微小结节中的诊断价值[J]. 中华耳鼻咽喉头颈外科杂志, 2014, 49 (11):893-896.DOI:10.3760/cma.j.issn.1673-0860.2014.11.004. Cited in this article [1]

[9]	Yassa L, Cibas ES, Benson CB, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation[J]. Cancer, 2007, 111(6):508-516.DOI:10.1002/cncr.23116. Cited in this article [1]

[10]	Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium[J]. Eur J Endocrinol, 2006, 154(6):787-803.DOI:10.1530/eje.1.02158. Cited in this article [1]

[11]	Ho AS, Sarti EE, Jain KS, et al. Malignancy rate in thyroid nodules classified as Bethesda category iii (AUS/FLUS)[J]. Thyroid, 2014, 24(5):832-839.DOI:10.1089/thy.2013.0317. Cited in this article [1]

[12]	Nikiforova MN, Nikiforov YE. Molecular diagnostics and predictors in thyroid cancer[J]. Thyroid, 2009, 19(12):1351-1361.DOI:10.1089/thy.2009.0240. Cited in this article [1]

[13]

Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules:a prospective analysis of 1 056 FNA samples[J]. J Clin Endocrinol Metab, 2011, 96(11):3390-3397.DOI:10.1210/jc.2011-1469. Cited in this article [1]

[14]	Moon HJ, Kwak JY, Kim EK, et al. The role of BRAFV600E mutation and ultrasonography for the surgical management of a thyroid nodule suspicious for papillary thyroid carcinoma on cytology[J]. Ann Surg Oncol, 2009, 16(11):3125-3131. DOI:10.1245/s10434-009-0644-9. Cited in this article [1]

[15]	Wojakowska A, Chekan M, Marczak Ł, et al. Detection of metabolites discriminating subtypes of thyroid cancer:molecular profiling of FFPE samples using the GC/MS approach[J]. Mol Cell Endocrinol, 2015, 417(12):149-157.DOI:10.1016/j.mce.2015.09.021. Cited in this article [1]

[16]	Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology:a review[J]. Clin Cancer Res, 2009, 15(2):431-440.DOI:10.1158/1078-0432.Ccr-08-1059. Cited in this article [1]

[17]	Patel S, Ahmed S. Emerging field of metabolomics:big promise for cancer biomarker identification and drug discovery[J]. J Pharm Biomed Anal, 2015, 107:63-74.DOI:10.1016/j.jpba.2014.12.020. Cited in this article [1]

[18]	Al-Zoughbi W, Al-Zhoughbi W, Huang J, et al. Tumor macroenvironment and metabolism[J]. Semin Oncol, 2014, 41(2):281-295.DOI:10.1053/j.seminoncol.2014.02.005. Cited in this article [1]

[19]	Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology[J]. Cell, 2017, 168(4):657-669.DOI:10.1016/j.cell.2016.12.039. Cited in this article [1]

[20]	Chen F, Dai X, Zhou CC, et al. Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma[J]. Gut, 2022, 71(7):1315-1325. DOI:10.1136/gutjnl-2020-323476. Cited in this article [1]

[21]	Ma Y, Chen H, Li H, et al. Intratumor microbiome-derived butyrate promotes lung cancer metastasis[J]. Cell Rep Med, 2024, 5(4):101488.DOI:10.1016/j.xcrm.2024.101488. Cited in this article [1]

[22]	Urayama S. Pancreatic cancer early detection:expanding higher-risk group with clinical and metabolomics parameters[J]. World J Gastroenterol, 2015, 21(6):1707-1717.DOI:10.3748/wjg.v21.i6.1707. Cited in this article [2]

[23]	Liu J, Geng W, Sun H, et al. Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma[J]. Gut, 2022, 71(6):1203-1213.DOI:10.1136/gutjnl-2021-325189. Cited in this article [1]

[24]	Du Y, Zou L, Fan P. Research of tissue metabolomics in papillary thyroid carcinoma based on HPLC/Q-TOF-MS[J]. Chin J Cancer Biother, 2020, 27(11):1264-1271.DOI:10.3872/j.issn.1007-385X.2020.11.009. Cited in this article [3]

[25]	Sun D, Zhang Y, Wang D, et al. Experimental study on changes in metabolic mechanism of papillary thyroid carcinoma complicated with hashimoto’s thyroiditis[J]. Heliyon, 2023, 9(10):e20661.DOI:10.1016/j.heliyon.2023.e20661. Cited in this article [3]

[26]	孙丹阳, 张玉洁, 李雪, 等. 基于超高效液相色谱混合四级杆飞行时间质谱技术的代谢组学探讨不同背景下甲状腺癌的代谢机制[J]. 中华内分泌代谢杂志, 2023, 39 (9):751-758.DOI:10.3760/cma.j.cn311282-20230118-00035. Cited in this article [3]

[27]	Abooshahab R, Hooshmand K, Razavi SA, et al. Plasma metabolic profiling of human thyroid nodules by gas chromatography-mass spectrometry (GC-MS)-based untargeted metabolomics[J]. Front Cell Dev Biol, 2020, 8:385.DOI:10.3389/fcell.2020.00385. Cited in this article [3]

[28]	Razavi SA, Mahmanzar M, Nobakht MGBF, et al. Plasma metabolites analysis of patients with papillary thyroid cancer:a preliminary untargeted (1)h NMR-based metabolomics[J]. J Pharm Biomed Anal, 2024, 241:115946.DOI:10.1016/j.jpba.2023.115946. Cited in this article [3]

[29]	Jiang N, Zhang Z, Chen X, et al. Plasma lipidomics profiling reveals biomarkers for papillary thyroid cancer diagnosis[J]. Front Cell Dev Biol, 2021, 9(6):682269.DOI:10.3389/fcell.2021.682269. Cited in this article [3]

[30]	Yu S, Liu C, Hou Y, et al. Integrative metabolomic characterization identifies plasma metabolomic signature in the diagnosis of papillary thyroid cancer[J]. Oncogene, 2022, 41(17):2422-2430.DOI:10.1038/s41388-022-02254-5. Cited in this article [3]

[31]	Jajin MG, Abooshahab R, Hooshmand K, et al. Gas chromatography-mass spectrometry-based untargeted metabolomics reveals metabolic perturbations in medullary thyroid carcinoma[J]. Sci Rep, 2022, 12(1):8397.DOI:10.1038/s41598-022-12590-x. Cited in this article [3]

[32]	Hellmann A, Turyn J, Zwara A, et al. Alterations in the amino acid profile in patients with papillary thyroid carcinoma with and without hashimoto’s thyroiditis[J]. Front Endocrinol (Lausanne), 2023, 14:1199291.DOI:10.3389/fendo.2023.1199291. Cited in this article [3]

[33]	Berinde GM, Socaciu AI, Socaciu MA, et al. Metabolic profiles and blood biomarkers to discriminate between benign thyroid nodules and papillary carcinoma,based on UHPLC-QTOF-ESI(+)-MS analysis[J]. Int J Mol Sci, 2024, 25(6):3495.DOI:10.3390/ijms25063495. Cited in this article [3]

[34]	Shi L, Guo M, Shi C, et al. Distinguishing benign and malignant thyroid nodules using plasma trimethylamine N-oxide,carnitine,choline and betaine[J]. J Cancer Res Clin Oncol, 2024, 150(3):142.DOI:10.1007/s00432-024-05666-w. Cited in this article [3]

[35]	D’Andréa G, Jing L, Peyrottes I, et al. Pilot study on the use of untargeted metabolomic fingerprinting of liquid-cytology fluids as a diagnostic tool of malignancy for thyroid nodules[J]. Metabolites, 2023, 13(7):782.DOI:10.3390/metabo13070782. Cited in this article [3]

[36]

Li L, Wen X, Li X, et al. Identifying potential breath biomarkers for early diagnosis of papillary thyroid cancer based on solid-phase microextraction gas chromatography-high resolution mass spectrometry with metabolomics[J]. Metabolomics, 2024, 20(3):59.DOI:10.1007/s11306-024-02119-w. Cited in this article [3]

[37]	Lu J, Zhang Y, Sun M, et al. Multi-omics analysis of fatty acid metabolism in thyroid carcinoma[J]. Front Oncol, 2021, 11:737127.DOI:10.3389/fonc.2021.737127. Cited in this article [3]

[38]	Wang Z, Yang Y, Xing Y, et al. Combined metabolomic and lipidomic analysis uncovers metabolic profile and biomarkers for papillary thyroid carcinoma[J]. Sci Rep, 2023, 13(1):17666.DOI:10.1038/s41598-023-41176-4. Cited in this article [3]

[39]	Sun Z, Feng D, Jiang L, et al. Integrated proteomic and metabolomic analysis of plasma reveals regulatory pathways and key elements in thyroid cancer[J]. Mol Omics, 2023, 19(10):800-809.DOI:10.1039/d3mo00142c. Cited in this article [3]

[40]	Jiang X, Liu Q, Xu D, et al. Integrated microbiome and metabolome analysis reveals a novel interplay between gut microbiota and metabolites in differentiated thyroid carcinoma[J]. BMC Microbiol, 2025, 25(1):346.DOI:10.1186/s12866-025-03877-w. Cited in this article [3]

[41]	Navas-Carrillo D, Rodriguez JM, Montoro-García S, et al. High-resolution proteomics and metabolomics in thyroid cancer:deciphering novel biomarkers[J]. Crit Rev Clin Lab Sci, 2017, 54(7-8):446-457.DOI:10.1080/10408363.2017.1394266. Cited in this article [1]

[42]	Bononi G, Masoni S, Di Bussolo V, et al. Historical perspective of tumor glycolysis:a century with Otto Warburg[J]. Semin Cancer Biol, 2022, 86(Pt 2):325-333.DOI:10.1016/j.semcancer.2022.07.003. Cited in this article [1]

[43]	Metere A, Graves CE, Chirico M, et al. Metabolomic reprogramming detected by (1)h-NMR spectroscopy in human thyroid cancer tissues[J]. Biology (Basel), 2020, 9(6):112. DOI:10.3390/biology9060112. Cited in this article [1]

[44]	Cararo Lopes E, Sawant A, Moore D, et al. Integrated metabolic and genetic analysis reveals distinct features of human differentiated thyroid cancer[J]. Clin Transl Med, 2023, 13(6):e1298.DOI:10.1002/ctm2.1298. Cited in this article [1]

[45]	Qu N, Chen D, Ma B, et al. Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks[J]. Nat Commun, 2024, 15(1):3175. DOI:10.1038/s41467-024-47581-1. Cited in this article [1]

[46]	Yang Z, Huang R, Wei X, et al. The SIRT6-autophagy-warburg effect axis in papillary thyroid cancer[J]. Front Oncol, 2020, 10:1265.DOI:10.3389/fonc.2020.01265. Cited in this article [1]

[47]	Hou X, Shi X, Zhang W, et al. LDHA induces EMT gene transcription and regulates autophagy to promote the metastasis and tumorigenesis of papillary thyroid carcinoma[J]. Cell Death Dis, 2021, 12(4):347.DOI:10.1038/s41419-021-03641-8. Cited in this article [1]

[48]	Liu C, Zhou X, Pan Y, et al. Pyruvate carboxylase promotes thyroid cancer aggressiveness through fatty acid synthesis[J]. BMC Cancer, 2021, 21(1):722.DOI:10.1186/s12885-021-08499-9. Cited in this article [1]

[49]	Ma S, Wang N, Liu R, et al. ZIP10 is a negative determinant for anti-tumor effect of mannose in thyroid cancer by activating phosphate mannose isomerase[J]. J Exp Clin Cancer Res, 2021, 40(1):387.DOI:10.1186/s13046-021-02195-z. Cited in this article [1]

[50]	Jing C, Li Y, Gao Z, et al. Antitumor activity of koningic acid in thyroid cancer by inhibiting cellular glycolysis[J]. Endocrine, 2022, 75(1):169-177.DOI:10.1007/s12020-021-02822-x. Cited in this article [1]

[51]	Liu CL, Hsu YC, Lee JJ, et al. Targeting the pentose phosphate pathway increases reactive oxygen species and induces apoptosis in thyroid cancer cells[J]. Mol Cell Endocrinol, 2020, 499:110595.DOI:10.1016/j.mce.2019.110595. Cited in this article [1]

[52]	Zhang X, Guo N, Jin H, et al. Bisphenol a drives di(2-ethylhexyl) phthalate promoting thyroid tumorigenesis via regulating HDAC6/PTEN and c-MYC signaling[J]. J Hazard Mater, 2022, 425:127911.DOI:10.1016/j.jhazmat.2021.127911. Cited in this article [1]

[53]	Ping P, Ma Y, Xu X, et al. Reprogramming of fatty acid metabolism in thyroid cancer:potential targets and mechanisms[J]. Chin J Cancer Res, 2025, 37(2):227-249.DOI:10.21147/j.issn.1000-9604.2025.02.09. Cited in this article [1]

[54]	Valvo V, Iesato A, Kavanagh TR, et al. Fine-tuning lipid metabolism by targeting mitochondria-associated acetyl-CoA-carboxylase 2 in BRAF(V600E) papillary thyroid carcinoma[J]. Thyroid, 2021, 31(9):1335-1358.DOI:10.1089/thy.2020.0311. Cited in this article [1]

[55]	Kim YH, Yoon SJ, Kim M, et al. Integrative multi-omics analysis reveals different metabolic phenotypes based on molecular characteristics in thyroid cancer[J]. Clin Cancer Res, 2024, 30(4):883-894.DOI:10.1158/1078-0432.Ccr-23-2025. Cited in this article [1]

[56]	Yuan L, Wang Z, Zhang D, et al. Metabonomic study of the intervention effects of parthenolide on anti-thyroid cancer activity[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2020, 1150:122179.DOI:10.1016/j.jchromb.2020.122179. Cited in this article [1]

[57]	Liu B, Peng Y, Su Y, et al. Transcriptome and metabolome sequencing identifies glutamate and LPAR1 as potential factors of anlotinib resistance in thyroid cancer[J]. Anticancer Drugs, 2024, 35(8):741-751.DOI:10.1097/cad.0000000000001626. Cited in this article [1]

[58]	Xu Q, Wang J, Mao Y, et al. Combined braf and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1:synergistic effect and metabolic mechanisms[J]. Neoplasia, 2024, 52:100996.DOI:10.1016/j.neo.2024.100996. Cited in this article [1]

[59]	王佳琦, 许茜茜, 唐茜, 等. PIM1过表达对甲状腺乳头状癌细胞代谢组学的影响及意义[J]. 中国普通外科杂志, 2024, 33(11):1835-1845.DOI:10.7659/j.issn.1005-6947.2024.11.010. Cited in this article [1]

[60]	Lu G, Gao D, Jiang W, et al. Disrupted gut microecology after high-dose (131)I therapy and radioprotective effects of arachidonic acid supplementation[J]. Eur J Nucl Med Mol Imaging, 2024, 51(8):2395-2408.DOI:10.1007/s00259-024-06688-9. Cited in this article [1]

[61]	Zheng W, Tang X, Dong J, et al. Metabolomic screening of radioiodine refractory thyroid cancer patients and the underlying chemical mechanism of iodine resistance[J]. Sci Rep, 2024, 14(1):10546.DOI:10.1038/s41598-024-61067-6. Cited in this article [1]

[62]	Yu Y, Ning K, Liu X, et al. Per- and polyfluoroalkyl substances (PFAS) exposure is associated with radioiodine therapy resistance and dedifferentiation of differentiated thyroid cancer[J]. Environ Pollut, 2025, 367:125629.DOI:10.1016/j.envpol.2025.125629. Cited in this article [1]

[63]	Poff AM, Ari C, Seyfried TN, et al. The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer[J]. PLoS One, 2013, 8(6):e65522. DOI:10.1371/journal.pone.0065522. Cited in this article [1]

[64]	Xie Z, Zhang D, Chung D, et al. Metabolic regulation of gene expression by histone lysine β-hydroxybutyrylation[J]. Mol Cell, 2016, 62(2):194-206.DOI:10.1016/j.molcel.2016.03.036. Cited in this article [1]

[65]	Wang J, Xu Q, Xuan Z, et al. Metabolomics reveals the implication of acetoacetate and ketogenic diet therapy in radioiodine-refractory differentiated thyroid carcinoma[J]. Oncologist, 2024, 29(9):e1120-e1131.DOI:10.1093/oncolo/oyae075. Cited in this article [1]

[66]	Aggarwal A, Yuan Z, Barletta JA, et al. Ketogenic diet combined with antioxidant N-acetylcysteine inhibits tumor growth in a mouse model of anaplastic thyroid cancer[J]. Surgery, 2020, 167(1):87-93.DOI:10.1016/j.surg.2019.06.042. Cited in this article [1]